Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Lawrence Kenyon

Affiliations

  • Ceo, Pres, Cfo, Treas & Secy at Outlook Therapeutics Inc. (OTLK), 2019-10-15
  • Chief Financial Officer at Arno Therapeutics Inc (ARNI), 2014-02-27
  • President, Ceo And Cfo at Tamir Biotechnology Inc. (ACEL), 2012-07-25
  • Other at Par Pharmaceutical Companies Inc. (PRX), 2010-08-04
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
OTLK $0.90 25,000 Officer, Director 82,213 2019-02-07 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
OTLK $1.70 1,350 Officer, Director 8,926 2019-09-18 Filing
OTLK $1.70 1,350 Officer, Director 80,863 2019-09-18 Filing
ONS $0.87 10,100 Officer, Director 57,213 2018-09-18 Filing
ONS $1.13 26,165 Officer 67,313 2017-12-22 Filing
PRX $25.27 200 Officer 20,649 2010-03-03 Filing